StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Gamma-Linolenic acid

HCID 5280933
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
506-26-3
Standard-SMILES
CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)O
InChIKey
VZCCETWTMQHEPK-QNEBEIHSSA-N
Summenformel
C18H30O2
Durchschnittliche Molmasse
278,4 g/mol
Monoisotopische Masse
278,2245802

Überblick

Gamma-linolenic acid is a C18, -6 acid fatty acid comprising a linolenic acid having cis- double bonds at positions 6, 9 and 12. It has a role as a mouse metabolite, a plant metabolite and a human metabolite. It is a linolenic acid and an omega-6 fatty acid. It is a conjugate acid of a gamma-linolenate.

Namen und Bezeichner

Bevorzugter Name
Gamma-Linolenic acid
IUPAC
(6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid
Englischer Name
gamma-Linolenic acid
Summenformel
C18H30O2
Molmasse
278.43

Namen und Synonyme

gamma-Linolenic acid506-26-3GAMOLENIC ACID(6Z,9Z,12Z)-octadeca-6,9,12-trienoic acidgamma Linolenic Acid(Z,Z,Z)-6,9,12-Octadecatrienoic acid(6,9,12)-linolenic acidAcido gamolenicoAcide gamoleniquegamoleic acidGamolenic-acidAcidum gamolenicum
Weitere Namen anzeigen
γ-Linolenic acidy-Linolenic acid6,9,12-OCTADECATRIENOIC ACIDC06426Gamolenic18:3(n-6)FlunarizinFlunarizinaR- flax acid
gammalinolenic acid6,9,12-Octadecatrienoic acid, (Z,Z,Z)-all-cis-6,9,12-Octadecatrienoic acidDelta-linolenic acidSonova 400DTXSID70461706Z,9Z,12Z-octadecatrienoic acid78YC2MAX4O

Datenbank-Bezeichner

CAS
506-26-3
PubChem CID
5280933
DTXSID
DTXSID7046170
ChEMBL
CHEMBL464982

Eigenschaften

Berechnete Struktureigenschaften

XLogP
5,9
Polarare Oberfläche (TPSA)
37,3 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
13
Schwere Atome
20
Formalladung
0
Komplexität
301

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

LipidsFatty Acyls [FA] -> Fatty Acids and Conjugates [FA01] -> Unsaturated fatty acids [FA0103]
SpringerMaterials PropertiesChemical diffusion
Endocrine DisruptorsPotential endocrine disrupting compound
Physical DescriptionLiquid
Collision Cross Section · 2 Einträge

172.84 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

174.5 Ų [M-H]-

Physikochemische Eigenschaften

Schmelzpunkt
-12 · -12~-11℃
Siedepunkt
379.5 · 379.5±11.0 °C(Predicted)
Dichte
0.92 · 0.92
Brechungsindex

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 2.3% (1 of 43) of reports.

Warning

H315 (97.7%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 43 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory Information · 2 Einträge

Chemical: 6,9,12-Octadecatrienoic acid, (Z,Z,Z)-

6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Other Safety InformationEvaluation - Chemicals that are unlikely to require further regulation to manage risks to environment
Hazard Classes and CategoriesSkin Irrit. 2 (97.7%)

Sicherheitsdaten

F
8-10-23
wgk
3
hs_code
29161500
risk_code
36/37/38
hazard_code
Xi
safety_code
26-36
Speicherklasse
10 - Combustible liquids

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

D - Dermatologicals

QD - Dermatologicals

Protein BindingNo pharmacokinetic data available.
Pharmacodynamics · 1 Eintrag

Gamolenic acid is converted to PGE1, which exhibits anti-inflammatory, antithrombotic, antiproliferative, and lipid-lowering effects. PGE1 also induces smooth muscle relaxation and vasodilation. Gamolenic acid is an essential component of membrane phospholipids, including the mitochondrial membrane, where it enhances the the integrity and the fluidity of the membrane. **Bone and joint health:** In a pilot study of women with a mean age of 79.5 years and senile osteoporosis, the use of gamolenic acid in combination with calcium and eicosapentaenoic acid was associated with an increase in femoral bone density and lumbar spine density in comparison to placebo, where there were no observable changes. In clinical studies of patients with rheumatoid arthritis, treatment with gamolenic acid-containing oils resulted in an improvement in symptoms, measured by joint tenderness counts and scores, joint swelling scores, physician global assessment, and pain. **Inflammation:** A study demonstrated that oral administration of gamolenic acid suppressed human T-cell proliferation and activation by interfering with early events in the TcR/CD3-receptor–mediated signal transduction cascade. **Atherosclerosis:** In ApoE genetic knock-out mice, dietary gamolenic acid was shown to reduce the average medial layer thickness of the vessel wall and reduces the size of atherosclerotic lesions. **Diabetic complications:** In a clinical trial of patients with mild diabetic neuropathy or distal diabetic neuropathy, treatment with gamolenic acid was associated with improved symptoms in hot and cold threshold, sensation, tendon reflexes, and muscle strength. GLA ameliorated the inflammatory profile in diabetic nephropathy in rat studies. **Cancer:** In three human tumor cell lines (the neuroblastoma CHP-212, the tubal carcinoma TG, and the colon carcinoma SW-620), gamolenic acid elicited cytotoxic effects in tumours by blocking cell proliferation following incorporation into malignant cells. In both clinical and animal studies of breast cancer, gamolenic acid, in combination with tamoxifen, down-regulated the expression of estrogen receptors. **Skin disorders:** In an open study of patients with atopic dermatitis, which is a disorder related to a deficiency of delta-6-desaturase and inefficient conversion of linoleic acid to gamolenic acid, daily administration of gamolenic acid was associated with a significant increase in plasma GLA and DGLA levels in combination with an improvement of clinical signs of atopic dermatitis. **Respiratory disorders:** In patients with acute lung injury or acute respiratory distress syndrome, gamolenic acid was shown to reduce cytokine production and neutrophil recruitment into the lung. In patients with atopic asthma, gamolenic acid blocked _ex vivo_ synthesis of leukotrienes from whole blood and isolated neutrophils compared to the placebo group.

Zugehörige Reaktionen

31
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 5266
HRID 5266als Edukt
Reaktionsgleichung von HRID 24976
HRID 24976als Edukt
Reaktionsgleichung von HRID 28300
HRID 28300als Edukt
Reaktionsgleichung von HRID 28308
HRID 28308als Edukt
Reaktionsgleichung von HRID 273349
HRID 273349als Edukt
Reaktionsgleichung von HRID 432972
HRID 432972als Edukt
Reaktionsgleichung von HRID 432974
HRID 432974als Edukt
Reaktionsgleichung von HRID 988075
HRID 988075als Edukt
ZurückSeite 1 von 4

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
ChEBI
CHEBI:28661
UNII
78YC2MAX4O
EC Number
624-740-4
Nikkaji
J12.229G
1.48 · 1.48
Flammpunkt
110 °C · 110 °C - closed cup
storage temp.
-20 °C · -20°C
Löslichkeit
Chloroform (Sparingly), DMSO (Slightly), Methanol (Slightly)
Aggregatzustand
oil
pka
4.74 · 4.74±0.10(Predicted)
Farbe
Colorless
Biologische Quelle
synthetic
Merck
14 · 14,5507
BRN
1712253 · 1712253
Stabilität
Light Sensitive
InChI
1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13H,2-5,8,11,14-17H2,1H3,(H,19,20)/b7-6-,10-9-,13-12-
InChIKey
VZCCETWTMQHEPK-QNEBEIHSSA-N
SMILES
CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O
LogP
6.57 · 6.570 (est)
CAS Datenbank
506 · 506-26-3(CAS DataBase Reference)
NIST chemische Informationen
Gamolenic acid(506-26-3)
Hazard Classifications
Eye Irrit. 2Skin Irrit. 2STOT SE 3
Mechanism of Action · 1 Eintrag

Once gamolenic acid (GLA) is absorbed and converted to dihomo-gamolenic acid (DGLA), circulating DGLA fatty acids are converted to several lipid mediators with predominantly anti-inflammatory properties, such as prostaglandin-E1 (PGE1) and 15-HETrE. The anti-inflammatory effects of DGLA are attributed to both the anti-inflammatory properties of DGLA-derived metabolites and the ability of DGLA and its products to compete with arachidonic acid (AA) in the synthesis of pro-inflammatory potent eicosanoid products, such as prostaglandins, thromboxane and leukotrienes. Both PGE1 and 15-HETrE are known to suppress inflammation, promote vasodilation, lower blood pressure, inhibit smooth muscle cell proliferation, inhibit platelet aggregation, and exert anti-neoplastic activities. PGE1 is a potent vasodilator that binds to surface receptors on smooth muscle cells, increasing intracellular cAMP. PGE1 is binds to G protein coupled surface PGE (EP) receptors and prostacyclin (IP) receptors as a natural ligand. GLA is proposed to enhance calcium absorption, reduce excretion and increase calcium deposition in bone. It is proposed that GLA may suppress tumor growth _in vivo_ by increasing the expression of E-cadherin, a cell-to-cell adhesion molecule that acts as a suppressor of metastasis. Another possible mechanism of tumour suppression is that GLA also reduces tumor-endothelium adhesion, which is a key factor in the establishment of distant metastases, partly by improving gap junction communication within the endothelium. By targeting the inflammatory process involved in the pathogenesis of diabetic nephropathy, GLA inhibits the expression of inflammatory mediators that tend be elevated in diabetes, intracellular adhesion molecule-1 (ICAM-1) and monocyte chemoattractant protein-1 (MCP-1), thereby attenuates the recruitment and infiltration of monocytes or macrophages.

Biological Half-LifeNo pharmacokinetic data available.
Metabolism/Metabolites · 1 Eintrag

Via elongation mediated by elongase (ELOVL5), gamolenic acid is rapidly converted to dihomo-gamma-linolenic acid (DGLA), which is further cyclooxygenated to prostaglandin E1 (PGE1) via COX-1 or COX-2 enzymatic activity depending on the cell type. PGE1 may be metabolized to smaller prostaglandin remnants, primarily dicarboxylic acids, which undergo renal excretion. DGLA may be converted to 15-(S)-hydroxy-8,11,13-eicosatrienoic acid (15-HETrE) by 15-lipoxygenase enzyme. Although the enzymatic pathway is less predominant relative to ELOVL5 in most cells, DGLA may also be converted to arachidonic acid (AA) via delta-5-desaturate activity, where hydrogen atoms are selectively removed to create new double bonds F27]. Arachidonic acid is a precursor in the biosynthesis of prostaglandin E2, thromboxanes, and leukotrienes, which are potent inflammatory mediators and play an important role in inflammatory pathways.

Absorption, Distribution and Excretion · 4 Einträge

The findings from a pharmacokinetic study suggest that therapeutic levels of GLA can be achieved within a week. The fasting plasma GLA levels plateaued within seven days of beginning treatment, regardless of dose.

The metabolites of gamolenic acid is expected to undergo renal excretion.

No pharmacokinetic data available.

No pharmacokinetic data available.

Tissue LocationsAdipose Tissue
Cellular LocationsCytoplasm
Metabolite Pathwaysalpha-Linolenic acid metabolism

Verwendung und Herstellung

UsesUse (kg; approx.) in Germany (2009): >75
Anwendungen · 4 Einträge

Beschreibungγ-Linolenic acid (gamma-linolenic acid or GLA, INN and USAN gamolenic acid) is a fatty acid found primarily in vegetable oils. It is sold as a dietary supplement for treating problems with inflammation and auto-immune diseases, although its efficacy is disputed.

OccurrenceGLA is obtained from vegetable oils such as GLA safflower oil (Carthamus tinctorius), evening primrose (Oenothera biennis) oil, blackcurrant seed oil, borage oil, and hemp seed oil. GLA is also found in edible hemp seeds, oats, barley, and spirulina. Each contains varying amounts of the fatty acid, with GLA safflower oil at 40% GLA being a novel concentrated form. This is a new genetically modified oil and has been available in commercial quantities since 2011. It should be noted that conventional safflower oils have zero GLA. Borage oil ranges from 15 % to 20 % and evening primrose oil ranges from 8 % to 10 % GLA. The human body produces GLA from linoleic acid (LA). This reaction is catalyzed by Δ6 - desaturase (D6D), an enzyme that allows the creation of a double bond on the sixth carbon counting from the carboxyl terminus. LA is consumed sufficiently in most diets, from such abundant sources as cooking oils and meats. However, a lack of GLA can occur when there is a reduction of the efficiency of the D6D conversion (for instance, as people grow older or when there are specific dietary deficiencies) or in disease states wherein there is excessive consumption of GLA metabolites.

HistoryGLA was first isolated from the seed oil of evening primrose. This herbal plant was grown by Native Americans to treat swelling in the body. In the 17th century, it was introduced to Europe and became a popular folk remedy, earning the name king's cure-all. in 1919, Heiduschka and Lüft extracted the oil from evening primrose seeds and described an unusual linolenic acid, which they name γ-. Later, the exact chemical structure was characterized by Riley. Although there are α- and γ- forms of linolenic acid, there is no β- form. One was once identified, but it turned out to be an artifact of the original analytical process.

Verwendenγ-Linolenic Acid is a fatty acid found mainly in vegetable oil. Studies suggest that γ-Linolenic Acid may have immune regulating and anti-inflammatory effects. γ-Linolenic Acid has also been used in the treatment of atopic eczeme although its efficacy is

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

2,5-Undecadiyn-1-ol2,5-Undecadiene, 1-bromo-, (Z,Z)- (9CI)2,5-Undecadien-1-ol, (2Z,5Z)-LIGAMO-006LIGAMO-003LIGAMO-0046-Heptynoic acid methyl ester6-Heptynoic acidgamma-Linolenic acid methyl ester

Nachgelagerte Produkte

Linolensure13(S)-HPOTRE(GAMMA)

Ergänzende Hinweise

DefinitionChEBI: A C18, omega-6 acid fatty acid comprising a linolenic acid having cis- double bonds at positions 6, 9 and 12.